Match the current product before comparing it
The US collection currently lists Cyspera Intensive at $180. Its product description names cysteamine and isobionic-amide, and identifies a 7% cysteamine concentration. The ingredient list also includes glycolic acid, mineral oil, glycerin, shea butter and fragrance among the other components. Hydroquinone is not listed in that retrieved formula.
That is a different record from older Cyspera Pigment Corrector or three-step Intensive System descriptions that may appear in search results. A familiar brand name does not guarantee that an older concentration, package or routine describes the current item. We do not combine a historic system price with a newer single-product ingredient list.
Ask the seller to identify the actual package and current ingredients before buying. Our whole-formula guide is useful even when the product contains no hydroquinone: the base, other active ingredients and previous reactions remain part of the decision. An ingredient's absence does not establish that every alternative will be comfortable for every person.
The access limitation is part of this review
TinyFish retrieved the current US product description, ingredient list and $180 display. The US collection also listed the product at $180. An independent direct request to that same product URL returned a 404 response, while the older shop host returned an error in the research fetch. We cannot explain those differences from the evidence collected.
Accordingly, this is a documented public-page review, not a guarantee that a particular reader can order the item through that route. Regional storefront behavior, inventory and checkout eligibility were not established. If the product page does not load, begin from the current official US collection and confirm the exact item with the seller.
This limitation also prevents a delivered-price claim. The retrieved product page says tax is included and shipping is calculated at checkout. We did not submit a cart, test a discount or verify a return. A comparison should use the observed product price while leaving the actual payment and shipping terms to the current order record.
A rinse-off product needs its own instructions
The current description presents Intensive as a short-contact, rinse-off cream. It also contains a staged contact-time schedule and a later maintenance schedule. Those are manufacturer directions for the named product, not instructions to layer it into an existing prescription plan without review.
Someone already using hydroquinone, tretinoin, an exfoliating acid or another pigment product should discuss the combination with their clinician. A rinse-off format does not automatically remove the possibility of irritation. Likewise, the presence of cysteamine in the human body does not demonstrate that every topical concentration or formulation suits every skin history.
Do not borrow application instructions from another Cyspera version or from the CoreAge Spot On review. These products differ in ingredients and intended routine. The provider who knows the condition being treated can explain whether a change, a break or a separate assessment is appropriate.
What the comparative study actually found
A randomized, double-blinded trial reported by Nguyen and colleagues compared cysteamine cream with hydroquinone cream over 16 weeks. Twenty people were recruited and fourteen completed the study: five in the cysteamine group and nine in the hydroquinone group. The abstract reports improvement in both groups on a melasma severity measure.
The difference between groups was not statistically significant, and hydroquinone was generally better tolerated in that small study. The authors called for larger studies. These findings are more informative than a claim that all cysteamine products outperform all hydroquinone products, but the small sample and incomplete follow-up limit the conclusion.
We reviewed the abstract through Europe PMC, not the full methods. It does not establish that the currently advertised 7% Intensive formula is identical to the studied preparation. A nonsignificant difference also does not prove that two products are equivalent in every clinically important respect. This study supplies ingredient-category context, not a verified result for the bottle being sold now.
Keep manufacturer outcome claims attributed
Cyspera's page describes improvement in the appearance of pigmentation and advertises a relatively early visible-results window. Those are commercial claims. They are not a personalized timetable, and a public before-and-after gallery does not establish what proportion of all purchasers will experience the same change.
Our photograph guide explains why lighting, angle and an agreed clinical review point matter. A useful follow-up record documents the concern consistently. It should not become a home experiment in calculating a percentage improvement from differently lit pictures or deciding that a stronger product is automatically needed.
AAD emphasizes assessment of the reason for pigmentation and a broader treatment plan. A product category cannot distinguish melasma, irritation-related marks or another condition by itself. A changing or uncertain mark deserves assessment before it is treated as a cosmetic shopping problem.
Put tolerance and the next review in the plan
The retrieved ingredient list includes fragrance and glycolic acid. That does not diagnose an allergy or make the product unsuitable for everyone, but it gives a person with previous reactions specific information to discuss. Obtain the full current package list rather than relying only on the headline ingredient.
Our irritation and allergy guide explains why worsening symptoms should be described and assessed instead of accepted as proof that treatment is working. Its record-keeping approach applies when comparing alternatives, while any stop, restart or treatment instructions should come from the appropriate professional and product information.
Cyspera Intensive is therefore an alternative product record in this library, not an additional hydroquinone provider or a clinical winner. The provider comparison retains CoreAge's disclosed first position and separates its prescription pathway from this non-hydroquinone option. The useful next step is to resolve the product, purchase and care questions together.